Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for adva...
What risk factors (e.g., clinical trial outcomes, regulatory hurdles, competition) could materially affect the company's outlook?
How does the sentiment score of 30 affect market perception, and what is the analyst consensus on the stock?
What is the breakdown of R&D versus SG&A expenses, and are there any cost‑saving initiatives underway?
27 days ago